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Objectives: To estimate the incremental cost-effectiveness ratio (ICER) of dual-
mobility cups (MBH) when used instead of conventional cups (FBH) to help reduce 
dislocation rates following total hip replacement (THR) in France. MethOds: A 
Markov model simulated two cohorts of patients: one with MBH and one with FBH. 
Three different states of health were considered: “stable”, “dislocation/revision” and 
“death”. The model adopted a collective perspective and the time horizon of the 
model was lifetime. Dislocation/revision rates were estimated using two different 
sources: literature review and expert opinions (analysis 1) and analysis of the PMSI 
(French hospital database) of Patients having one THR in 2009 followed through the 
end of 2012 (analysis 2). Costs considered were hospitalization costs (reduction/
revision for dislocation performed in acute care unit and care in rehabilitation 
units), valued using the National Scale Costs with Common methodology (ENCC). 
Outpatients’ costs were considered for patients going back home after hospitaliza-
tion and valued by expert opinions and literature data. The model estimated the 
number of dislocations/revisions for each cohort and differences between the two 
groups in terms of QALY gained, costs and cost-effectiveness ratio. Deterministic 
and probabilistic sensitivity analyses (PSA) were conducted. Results: In analysis 
1 for a 100,000 THR cohort, 4,626 dislocations and 1,243 revisions were avoided. 
Total number of QALY gained was 894 and total economic gain € 44.7 million. In 
analysis 2, 3, 176 dislocations and 854 revisions were avoided for an economic gain 
of € 30.7 million and a gain of 611 QALY. Reported to 100,000 THR, the economic gain 
per MBH cup was € 447 or € 307. PSA estimated the mean ICER to € -55,693 per QALY 
gained. cOnclusiOns: Because of the current rules of tariffs used in France and 
given the absence of additional costs associated with the use of DM prosthesis, this 
strategy can be considered dominant in THR.
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Objectives: The purpose of this study was to estimate the cost-effectiveness of 
multiple anti-osteoporotic drug therapies for secondary prevention of fractures in 
elderly women with osteoporosis in Japan. MethOds: A state transition model 
with nine health states (seven types of post-fracture, bedridden, and death) was 
developed to predict lifetime costs and quality-adjusted life years (QALY) of no anti-
osteoporotic therapy and eight drug therapies in patients with a previous vertebral 
fracture. Incidence of hip, vertebral, and other fracture associated with age and 
bone mineral density (BMD) was estimated by using a regression approach based 
on epidemiologic studies in Japan. Comparative effectiveness of anti-osteoporo-
tic drug therapies was derived from a published network meta-analysis. For the 
base-case analysis, we ran the model with T-score of -2.5 and different age (65, 70, 
and 75 years). Probabilistic sensitivity analysis was performed to assess param-
eter uncertainty. Results: Alendronate therapy dominated all other strategies, 
resulting in 11.746 QALY and lifetime costs of $34,568. Compared to no preventive 
therapy, alendronate conferred an additional 0.458 QALY and saved lifetime costs of 
$13,753. Risedronate was equally cost-effective, resulting in 11.731 QALY and costs 
of $34,932. Applying a willingness to pay threshold of $50,000 per QALY, the prob-
ability of being cost-effective were estimated to 76.2 % and 23.8% for alendronate 
and risedronate, respectively. These results did not change in women aged 70 and 75 
years. cOnclusiOns: Bisphosphonate therapies for secondary prevention of frac-
tures in elderly women would be cost-effective in terms of Japan health care system.
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Objectives: Evaluate most rationale medical technology in the rheumatoid 
arthritis therapy (RA) (comparison of alternatives – GEBDs Tofacitinib and bio-
logics: Infliximab, Abatacept, Certolizumab pegol, Golimumab, Adalimumab and 
Tocilizumab) from pharmacoeconomic analysis point of view. MethOds: Analysis 
based on the assessment for one statistically average patient suffering from RA, 
and weighing 70 kilograms, over a one year course of treatment (52 weeks). The 
analysis done of direct costs included: cost of DMARDs and biologics therapy use; 
costs of drug introduction; physician visits cost. Cost-minimization and missed 
opportunities analysis were used. Results: During the effectiveness analysis 
of RA treatment, based on the meta-analyses of randomized placebo-controlled 
trials data (including meta-analyses P. Kawalec, 2013; E. Salgado, 2013), Russian 
and international RA treatment recommendations, it was concluded that there 
was no statistically significant difference in efficacy and toxicity of the Tofacitinib 
and the biologics used in the RA treatment. One year treatment course with 
Tofacitinib, Infliximab, Abatacept, Golimumab, Certolizumab pegol, Adalimumab 
and Tocilizumab cost, include subcutaneous route of administration, will amount 
to 12.818 EUR, 20.932 EUR, 14.855 EUR, 18.104 EUR, 19.642 EUR, 20.120 EUR and 21.664 
EUR, respectively. cOnclusiOns: During pharmacoeconomic analysis was defined 
that therapy with Tofacitinib in comparison with biologics use will reduce the cost 
of a one year course of treatment for each RA patient from 2.037 EUR to 8.846 EUR. 
Transition of 100 RA patients onto a treatment regimen, includes Tofacitinib use, 
will make it possible to treat from 15 to 69 patients more suffering from this disease.
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to measure quality of life. The clinical parameters used in the model take into 
account the results from a MTC of clinical trials. In order to adapt the model to 
the Portuguese context, several adjustments were made to its original version. 
These mainly relate to mortality rates by gender and to the unit costs of medical 
resources, such as drugs, medical visits, admissions, ancillary tests and so on, 
that were obtained from public official sources. We applied a 5% discount rate and 
conducted an analysis for a hypothetical cohort of 1,000 patients. Results: The 
treatment of RA with etanercept is more expensive than that with the comparator. 
Nevertheless, QALYs gained do compensate for the additional costs. Overall, ICER 
is € 12,853, which is below the usual willingness to pay threshold used in Portugal. 
A sensitivity analysis was carried out, which confirmed the robustness of these 
results. cOnclusiOns: According to our analysis, etanercept is a cost-effective 
alternative versus golimumab for the treatment of rheumatoid arthritis. Its main 
advantage over the selected comparator relates to the associated improvements 
in health related quality of life.
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Objectives: To determine the cost-effectiveness of pegloticase (Krystexxa®) for 
patients with severe debilitating chronic tophaceous gout (SDCTG), from a UK health 
care perspective. MethOds: Severe debilitating chronic tophaceous gout (SDCTG) 
is a debilitating disease, with high unmet medical need. Existing treatments mainly 
provide symptom relief and do not modify the disease course. Pegloticase has the 
potential to be a disease modifying agent. A decision analytical model was built to 
compare the use of pegloticase in patients with SDCTG with best supportive care 
(BSC) with a Markov model used to extrapolate outcomes to a 20 year time-horizon. 
In the basecase, the disease modifying properties of pegloticase were modelled. 
In scenario analyses only symptomatic relief of pegloticase on acute attacks and 
tophi was included. Results: In the basecase, the cost-effectiveness of pegloti-
case compared to BSC was £31,027 per QALY gained. In this basecase, pegloticase 
dramatically reduced the uric acid burden in over 60% of patients who completed a 
six month course and were assumed could then be controlled on xanthine oxidase 
inhibitor maintenance treatment. In a pessimistic scenario whereby pegloticase was 
assumed to only provide symptomatic relief, the ICER was £48,672/QALY gained. In a 
further scenario whereby utility benefits were limited to only short-term reduction 
in acute flares and presence of tophi, the ICER was £54,345/QALY. Apart from these 
two drivers, the cost-effectiveness estimates were relatively stable across a range 
of sensitivity analyses. cOnclusiOns: In the context of a highly severe and debili-
tating form of gout, with small patient numbers and a lack of alternative effective 
treatment options, pegloticase can be considered good value-for-money. Further 
clinical evidence is required to demonstrate the disease modifying properties of 
pegloticase. However, such data collection and hence the ability to perform robust 
economic evaluations for HTA purposes is difficult especially when the sponsoring 
company is small with limited funds.
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Objectives: The prevalent vertebral fracture (VF) is a risk factor for future VF, which 
can be decreased with drug therapy. However, most VFs are not recognized clinically. 
Vertebral fracture assessment (VFA) by dual-energy x-ray absorptiometry (DXA) and 
spine x-ray can be performed to detect these prevalent VFs. This study aimed to 
estimate the costs, effectiveness, and radiation exposure of VF diagnostic strate-
gies. MethOds: Markov model over a 10-year period was used to calculate the 
medical costs for diagnostic tests and VF treatment, the reduction of incident VFs 
of patients who have experienced a VF, and the radiation doses in target population 
aged over 50. We compared three strategies: ‘VFA followed by confirmatory radi-
ography (VFA screening)’, ‘only VFA’ and ‘only x-ray’ every 2 years, to ‘no screening 
before recognition’. We assumed that all patients tested positive for VF received drug 
therapy. A discount rate of 5% was applied in cost. Results: The results showed the 
incremental costs for women over age 50 who had VFA screening, only VFA, and only 
x-ray were $1,112, $1,546, and $1,270 per person, respectively. Future VF incidence 
was reduced by 29% in both VFA screening and only VFA and 35% in only x-ray as 
compared with no screening for 10 years. Radiation exposure was highest in the 
only x-ray strategy. Also, the effectiveness and medical costs were more increased 
in female and old age people than in male and over age 50. The sensitivity analyses 
showed that these results are robust to variety assumptions including cycle length, 
medical costs, and diagnostic accuracy. cOnclusiOns: This study suggests that 
VFA screening strategy can be relevant option for new VF prevention as considering 
lower cost and less radiation. This study is expected to provide useful information 
as establishing the VF diagnostic strategy in clinical practice.
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